Comprehensive Clinical Note on Classic Hodgkin Lymphoma (cHL)

Pathobiology and Cellular Composition of Classic Hodgkin Lymphoma

Classic Hodgkin Lymphoma (cHL) is a specific type of lymphoid malignancy characterized by the presence of Hodgkin/Reed-Sternberg (HRS) cells. These malignant cells are unique because they typically constitute only a small fraction of the total tumor mass, often described as "thieves" hiding within a vast microenvironment of non-malignant "soldier" cells. This reactive background is pleomorphic and inflammatory, consisting of small lymphocytes, eosinophils, neutrophils, histiocytes, plasma cells, and fibroblasts, sometimes accompanied by collagen deposition or fibrosis. The HRS cells themselves are large, often multinucleated or polylobated, and characterized by prominent, "owl-eye" nucleoli. The broader category of HRS cells includes several variants: classic Reed-Sternberg (RS) cells, mononuclear Hodgkin cells, lacunar cells, and mummified cells (degenerate forms).

The origin of HRS cells is traced to B cells within the germinal center. Throughout their development, these cells undergo a transformation where they lose their ability to express standard B-cell markers and immunoglobulins, as well as other factors that define normal B cells. Despite this loss, they carry genetic mutations, including rearrangements of the immunoglobulin heavy chain ($IGH$) genes, which can be identified through molecular techniques like Polymerase Chain Reaction (PCR). These cells do not correspond to any normal stage of B-cell development and maintain survival through aberrant immune signaling pathways.

Molecular Signaling and Immune Evasion Mechanisms

The survival and proliferation of HRS cells are driven by the activation of abnormal cellular signaling pathways, including $NF-\kappa B$, $JAK/STAT$, $NOTCH$, and $PI3K/AKT/ERK/MAPK$. These pathways promote the expression of various cytokines and chemokines such as $IL-8$, $IL-17$, $CCL5$, and $CCL17$. These secreted factors actively recruit diverse immune cells into the tumor microenvironment, including regulatory T cells ($T_{reg}$) and myeloid-derived suppressor cells (MDSC), which create a supportive environment for the tumor while suppressing anti-tumor immune responses.

Immune evasion is a hallmark of cHL, achieved through several strategic impairments of the immune system. HRS cells frequently exhibit a downregulation of Major Histocompatibility Complex (MHC) Class $I$ and Class $II$ expression due to mutations in genes such as $\beta 2M$ and $CIITA$, effectively hiding them from T-cell recognition. Furthermore, there is a significant overexpression of Programmed Death-Ligands $1$ and $2$ ($PD-L1$ and $PD-L2$), often resulting from the amplification of the $9p24.1$ chromosomal region. These ligands bind to the $PD-1$ receptor on T cells, acting as a "molecular brake" that induces T-cell exhaustion and prevents them from attacking the tumor. Additionally, HRS cells secrete suppressive substances like $TGF-\beta$, $IL-10$, and $IL-1\beta$ to further inhibit the immune system and escape programmed cell death (apoptosis).

Clinical Epidemiology and Risk Factors

Classic Hodgkin Lymphoma accounts for approximately $10\%$ of all lymphomas in developed nations. It follows a distinct bimodal age distribution, with the first peak occurring in young adults between the ages of $15$ and $35$ years, and a second peak occurring in older adults between $60$ and $80$ years. Socioeconomic status influences the prevalence of specific subtypes; for instance, Mixed Cellularity (MC) and Lymphocyte-Depleted (LD) subtypes are more common in rural areas or populations with lower standards of living, whereas the Nodular Sclerosis (NS) subtype is more prevalent in urban areas and populations with higher socioeconomic status.

Infectious agents play a significant role in the etiology of cHL. The Epstein-Barr Virus (EBV) is strongly associated with the disease, particularly in the MC and LD subtypes, where EBV positivity can reach up to $100\%$. While other viruses such as $HHV-6$, $HHV-7$, $HHV-8$, and $CMV$ have been studied, there is no convincing evidence of their causal role. Immunosuppression significantly elevates risk; individuals living with HIV have a $5$ to $25$-fold increased risk of developing cHL, and these cases are almost exclusively EBV-positive. Increased risk is also observed in transplant recipients and those on immunosuppressive or steroid therapies. Genetic factors are also evident, as individuals with a first-degree relative diagnosed with cHL face a $3$ to $5$-fold higher risk, with the risk being particularly strong among siblings. Additionally, autoimmune diseases such as Rheumatoid Arthritis (RA), Sjögren's syndrome, and Psoriasis are linked to an increased risk, though this may be related more to immunosuppressive treatments than the diseases themselves.

Histological Subtypes of Classic Hodgkin Lymphoma

There are four primary histological subtypes of cHL, each with unique professional characteristics. Nodular Sclerosis (NS) is the most frequent, representing approximately $70\%$ of cases in developed countries. It is characterized by well-defined cellular nodules surrounded by broad, concentric bands of birefringent collagen. The predominant malignant variant in this subtype is the lacunar cell. Mixed Cellularity (MC) involves $20-25\%$ of cases and features scattered HRS cells within a diverse inflammatory background without the dense collagen bands seen in NS. Lymphocyte-Rich (LR) accounts for about $5\%$ of cases and exhibits a nodular architecture that can resemble Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL); however, it is distinguished by a small number of HRS cells with a classic immunophenotype ($CD30+$, $CD15+$) within a background of mostly B-cell follicles. Lymphocyte-Depleted (LD) is the rarest subtype, occurring in less than $1\%$ of cases, and is characterized by numerous atypical RS cells, heavy fibrosis, and a sparse inflammatory infiltrate, often presenting a sarcomatous appearance.

Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL) is a distinct clinical entity that shares some features with cHL but differs significantly in its epidemiology, clinical course, and treatment. It is characterized by "LP" (lymphocyte predominant) cells and a different immunophenotype that retains B-cell markers.

Clinical Presentation and Symptomatic Patterns

The most common presentation of cHL, occurring in about $2/3$ of cases, is painless, firm, and rubbery lymphadenopathy. The most frequently involved sites are the cervical nodes ($60-80\%$), followed by axillary nodes ($30\%$) and inguinal nodes ($10\%$). Involvement of the sub-diaphragmatic nodes alone is rare ($<10\%$). Disease typically spreads contiguously from one lymph node region to adjacent regions via lymphatic vessels. Non-contiguous or hematogenous spread is rare and more common in immunosuppressed patients, such as those with HIV. Mediastinal involvement is very common and can manifest as a large mass discovered on a routine chest X-ray, sometimes before symptoms appear. Symptoms of a mediastinal mass include cough, shortness of breath, chest pain, and in rare cases, Superior Vena Cava Syndrome. Pleural or pericardial effusions are occasionally seen, particularly in bulky disease.

Systemic "B symptoms" occur in approximately $40\%$ of patients and include persistent fever ($>38^\circ\text{C}$), drenching night sweats, and unexplained weight loss of more than $10\%$ of body weight within six months. These symptoms are negative prognostic factors. Pruritus (generalized itching) occurs in $10-15\%$ of cases and can be severe enough to cause skin excoriation; while it can precede diagnosis by months, it is not officially classified as a B symptom. A highly specific but rare ($<10\%$) symptom is severe pain in involved lymph node areas occurring within minutes of alcohol consumption. Other findings may include abdominal pain, nausea, or anorexia due to liver or splenic involvement. Rare paraneoplastic syndromes can occur, including neurological findings like cerebellar degeneration, chorea, neuromyotonias, or limbic encephalitis, as well as nephrotic syndrome (most commonly Minimal Change Disease).

Diagnostic Evaluation and Biopsy Standards

A definitive diagnosis of cHL requires a biopsy to identify the HRS cells and determine the histological subtype. Excisional biopsy of an entire lymph node is the gold standard and is highly preferred over incisional or needle biopsies. Because HRS cells are scarce and hidden amongst many normal lymphocytes, a fine-needle aspiration (FNA) is generally insufficient for a definitive diagnosis as it does not provide enough tissue architecture. Core needle biopsy (CNB) may be sufficient in some cases but is less reliable than an excisional biopsy. When choosing a site for biopsy, cervical, supraclavicular, or axillary nodes are preferred over inguinal nodes, as the latter often show non-specific reactive changes that can obscure the diagnosis.

For internal masses, such as those in the mediastinum, sampling may require more invasive procedures like Video-Assisted Thoracoscopic Surgery (VATS), mediastinoscopy, or anterior mediastinotomy. CT-guided biopsies are less recommended due to potential tissue damage (crush artifact) and limited sample size. Diagnostic evaluation also involves assessing extranodal involvement. While bone marrow biopsy is no longer routine if a PET-CT is performed (due to the high sensitivity of PET for marrow involvement), it may still be considered if there are unexplained cytopenias. Splenic involvement is often assessed via imaging (CT, PET, or MRI), where it often appears as diffuse infiltration with miliary lesions or focal nodules. Liver involvement is rare as an isolated finding and usually requires confirmation by imaging or biopsy if liver function tests are abnormal or symptoms like jaundice are present.

Staging, Risk Stratification, and Pre-Treatment Preparation

Staging is primarily performed using PET-CT, which is more accurate than conventional CT for initial staging. PET-CT has a $41\%$ upstaging rate, largely due to the identification of extranodal or bone involvement, and a $10\%$ downstaging rate. The Deauville criteria are used for evaluating response to treatment based on PET findings. Bulky disease is defined as a lymph node mass $\geq 10\,\text{cm}$ in diameter or a mediastinal mass exceeding $1/3$ of the internal thoracic diameter on CT. Splenomegaly is typically defined as a splenic diameter $>13\,\text{cm}$. Risk stratification is performed using models from organizations like the German Hodgkin Study Group (GHSG) or EORTC/LYSA to categorize patients into favorable or unfavorable early-stage or advanced-stage groups, which guides treatment selection.

Before initiating treatment, a comprehensive medical assessment is necessary. This includes evaluating performance status via Karnofsky or ECOG scales and checking organ function. For patients considering anthracycline-based regimens like ABVD, an echocardiogram or MUGA scan is required to ensure a Left Ventricular Ejection Fraction (LVEF) $\geq 50\%$. For those receiving Bleomycin, pulmonary function tests including DLCO are mandatory, with a required threshold of $\geq 60\%$. Laboratory tests must include HBsAg, anti-HBc, HCV, and HIV serology, as well as pregnancy tests for women of childbearing age. Fertility preservation should be discussed; cryopreservation of sperm is recommended for men, and fertility preservation options should be considered for women, especially those over $30$ years of age or those facing intensive salvage therapy.

Therapeutic Principles and Immunotherapy

The treatment of cHL has evolved to include targeted immunotherapies, specifically PD-1 inhibitors like Nivolumab and Pembrolizumab. The rationale for these treatments lies in the genetic makeup of HRS cells, which often feature an amplification of the $9p24.1$ region, leading to the over-expression of $PD-L1$ and $PD-L2$. These ligands "turn off" T cells by binding to the $PD-1$ protein, which acts as a checkpoint or "brake" on the immune system to prevent overactivity. By blocking the $PD-1$ receptor, medications like Nivolumab prevent the tumor from inactivating T cells, thereby allowing the immune system to recognize and attack the malignant cells. These therapies have proven particularly effective in Hodgkin Lymphoma. Follow-up after treatment generally extends for up to $5$ years to monitor for recurrence and long-term side effects.

Questions & Discussion

Does Flow Cytometry have a role in the diagnosis of Hodgkin Lymphoma? No, flow cytometry does not have a diagnostic role in Hodgkin Lymphoma. In other types of lymphomas, flow cytometry is used to determine if there is a clonal population of cells by checking for light chain restriction (Kappa or Lambda) on the surface of B cells. Because HRS cells are so rare in the tissue sample and do not express these standard markers, flow cytometry is not helpful for identifying them or staging the disease. The diagnosis and immunophenotyping of cHL rely strictly on immunohistochemistry performed on tissue sections.